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The State of Alaska Department of Health and Social Services (DHSS), Division of Behavioral Health (DBH) 
was awarded the Partnerships for Success (PFS) grant by the Substance Abuse and Mental Health 
Services Administration (SAHMSA) in 2015. DBH contracted with the Center for Behavioral Health 
Research and Services (CBHRS) at the University of Alaska Anchorage (UAA) to conduct a comprehensive 
project evaluation. As part of the evaluation, CBHRS performed a baseline assessment of the state’s 
capacity and infrastructure related to prescription opioid misuse prevention. 
Researchers conducted interviews with key stakeholders representing state government, healthcare 
agencies, law enforcement, substance abuse research, and service agencies. Interviews were semi-
structured, with questions addressing five domains of interest: (1) state climate and prevention efforts; 
(2) partnerships and coordinated efforts; (3) policies, practices, and laws; (4) data and data monitoring; 
and (5) knowledge and readiness. Thirteen interviews were conducted and analyzed using a qualitative 
template analysis technique combined with a SWOT analysis (i.e. strengths, weaknesses, opportunities, 
and threats). Emergent themes are displayed in Table 1 below.  
Table 1. Emergent themes from SWOT analysis 
Strengths Weaknesses Opportunities Threats 
(1) New and revised 
policies and 
guidelines 
(2) Activities and 
partnerships 
between state 
agencies and 
communities 
(3) Knowledge and 
awareness of state 
leadership 
(1) State policy 
limitations 
(2) Insufficient detox, 
treatment, and 
recovery support 
resources 
(3) Lack of full 
coordination within 
state agencies and 
with communities 
(1) Education enrichment 
(2) Policy improvements 
(3) Expansion of 
treatment, recovery, 
and mental health 
support 
(1) State fiscal crisis 
(2) Prescribing practices 
(3) Complexity and 
stigma of addiction 
(4) Legislative support 
Despite limitations in sample representativeness and interview timing, participants agreed that 
agencies, communities, and organizations across Alaska have demonstrated great concern about the 
opioid epidemic and that this concern has translated into considerable efforts to address and prevent 
opioid misuse. Participants also noted a variety of opportunities as targets for future work, many of 
which would address some of the current weaknesses that exist. Results yielded clear recommendations 
for increasing awareness and providing education to a variety of groups, further improving relevant 
policies to promote prevention, and expanding services for prevention and treatment. 
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In September of 2015, SAMSHA awarded the PFS grant to the State of Alaska DHSS, DBH. This five-year 
grant program focuses on preventing and reducing substance use and building prevention capacity and 
infrastructure at both the state and community level. Two priority areas were chosen for the Alaska PFS 
grant: non-medical use of prescription opioids among 12-25 year olds and heroin use among 18-25 year 
olds. [Please see Alaska’s Partnership for Success Grant – Technical Report 1 for quantitative data 
summaries related to these two priority areas.] 
The PFS project funds community-level coalitions to engage in prevention and intervention activities; 
DBH provides leadership for the project and guidance to the coalitions and works to help strengthen the 
state’s prevention capacity and infrastructure. DBH contracted with the Center for Behavioral Health 
Research and Services (CBHRS), part of the Institute of Social and Economic Research (ISER) at the 
University of Alaska Anchorage (UAA), to conduct a comprehensive evaluation of the PFS project.  
Strategic Prevention Framework 
Drawing on a public health approach to behavioral 
health prevention, the SPF uses a data-driven process of 
five steps: 1 - assessment (i.e., identify the extent of 
the problem and the contributing factors); 2 - build 
capacity (i.e., identify resources and readiness); 3 - 
plan (i.e., develop a plan to address the problem and 
build capacity); 4 - implement (i.e., put the plan into 
action); and 5 - evaluate (i.e., determine 
effectiveness).1 As illustrated in Figure 1, the steps are 
related and the process can often be iterative. The SPF 
also includes two core principles: cultural competence 
and sustainability. The principle of cultural competence 
emphasizes the importance of working and interacting 
effectively with individuals of different cultures and 
being respectful and responsive to cultural differences. 
The focus of sustainability is to ensure that effective programs that achieve prevention outcomes can 
persist. Sustainability involves garnering support from stakeholders and communities, demonstrating 
effectiveness and results, and acquiring ongoing funding and resources. 
State Capacity & Infrastructure 
The capacity and infrastructure of Alaska is an important factor that will contribute to the success of the 
PFS project. In this context, capacity is Alaska’s readiness and ability to address opioid misuse among 
Alaskans and the related problems occurring in the state. Capacity includes funding and resources 
allocated for addressing opioid issues. Infrastructure is defined as the fundamental elements of the 
systems working to address opioid issues and includes climate, policies, and partnerships. Assessment of 
the existing capacity and infrastructure allows for the identification of those resources and structural 
                                                   
1 Substance Abuse and Mental Health Services Administration, “Applying the Strategic Prevention Framework (SPF),” Center for the Application 
of Prevention Technologies, last modified June 22, 2016, https://www.samhsa.gov/capt/applying-strategic-prevention-framework. 
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Figure 1: Substance Abuse and Mental Health 
Services Administration - Strategic Prevention 
Framework.1 
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elements addressing non-medical use of prescription opioids, recognition of any gaps, and information 
to develop recommendations to enhance opioid prevention efforts through PFS activities.  
To determine a baseline from which to evaluate the impact of the PFS project on Alaska’s capacity and 
infrastructure related to opioid misuse prevention in Alaska, researchers from CBHRS conducted key 
informant interviews with stakeholders from a variety of relevant sectors. While the overall PFS project 
aims to address both prescription opioid misuse and heroin use, the capacity and infrastructure 
evaluation is specific to prescription opioids, the primary substance of focus for the PFS project. In 
addition to serving as a baseline, results from this assessment will assist the state and funded 
communities in identifying opportunities to enhance capacity and infrastructure for opioid misuse 
prevention.  
 
 
A semi-structured interview model was used to assess prevention capacity and infrastructure at the 
state level. This activity was reviewed and approved by the UAA Institutional Review Board (IRB) for 
research with human subjects.  
Key stakeholders were interviewed to gather their perspectives on five domains:  
(1) State climate and prevention efforts 
(2) Partnerships and coordinated efforts 
(3) Policies, practices, and laws 
(4) Data and data monitoring 
(5) Knowledge and readiness 
The interview guide consisted of a small number of scaled questions and a series of open-ended 
questions in each domain. Responses to the scaled questions will be used to compare responses from 
this administration (baseline) to responses provided during follow-up administration at the end of the 
PFS project in 2019. Open-ended questions extracted in-depth context for the numbered response and 
other information unique to the domain such as participants’ perceptions of what is working well, what 
is not working well, areas of improvement, and any new ideas related to the domain. The interview 
guide included additional probing questions for use as needed. Closing questions provided participants 
the opportunity to offer any further comments or suggestions. 
Participant Recruitment 
Potential interview participants were identified based on either an individual’s leadership position in the 
Alaska state government or involvement with and knowledge of current state-level efforts related to 
prescription opioid misuse. These individuals represented a variety of state departments and local 
agencies such as State of Alaska DHSS, law enforcement, education, service organizations, healthcare 
and treatment organizations, and pharmacies.  
Potential key informants were contacted by email to request their participation in the baseline 
interviews. Initial emails were sent in July 2016 and described the purpose of the interview, explained to 
individuals why their participation was important and included an attached consent form. Participants 
were asked to respond via email or phone if they were willing to participate and interviews were 
scheduled. Follow-up emails were sent in mid-September with a letter of support from the leadership of 
the Alaska Department of Health and Social Services, Division of Behavioral health. 
Methodology 
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The initial recruitment effort yielded a smaller-than-expected response. Thus, a second group of 
potential participants was identified, and those individuals were also invited to participate. For non-
responders, final attempts to contact were made via telephone.   
Between July 2016 and November 2016, 27 potential key informants were contacted and invited to 
participate.  
Interviews 
Sixteen (16) key informants agreed to participate and were interviewed via telephone. The interviews 
began with a review of the IRB-approved informed consent, including language ensuring participation 
was voluntary. Before starting the interview, the interviewer gave participants the opportunity to ask 
questions or voice concerns about the interview or informed consent. Each respondent gave verbal 
consent to participate in an interview and be audio recorded prior to completion of the semi-structured 
interview. Interviews ranged from fifteen to ninety minutes in duration. Once completed, interviews 
were transcribed verbatim and uploaded into NVivo qualitative data software for analysis. 
Three of the key informants did not participate fully in the interviews, resulting in insufficient 
information for analysis. Reasons included lack of relevant knowledge, insufficient confidence to 
respond accurately to questions and prompts, and misconceptions about the purpose of the interviews. 
Therefore, of the sixteen interviews performed, thirteen were retained and analyzed. 
Qualitative Analysis 
A thematic template analysis technique was used to construct a coding guide for analysis of the 
interviews. Template analysis is a preferred qualitative analysis technique when researchers have pre-
existing ideas of structured themes before beginning analysis.2 In building the first coding template, the 
primary coding themes were the five domains used in the interview guide (i.e., climate; partnership; 
policies, laws, and practices; data; knowledge and readiness). 
Given the questions in the interview guide and the goal of analysis, the data was also suitable for a 
SWOT (i.e. strengths, weaknesses, opportunities, threats) analysis. The final coding template combined 
the five domains with a basic SWOT structure to organize themes. 
All data was coded initially by a single researcher for domain(s) and SWOT category. Cross-analysis of 
the domains by SWOT categories allowed for the identification of similar or overlapping content and the 
organization of data into themes.   
Table 2. SWOT analysis table 
 Strengths Weaknesses Opportunities Threats 
Climate     
Partnership     
Policies, Laws, & Practices     
Data     
Knowledge & Readiness     
                                                   
2 Nigel King, “Doing Template Analysis,” in Qualitative Organizational Research: Core Methods and Current Challenges, ed. Gillian Symon and 
Catherine Cassell (London, UK: SAGE Publications Ltd, 2012), 428-429.  
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A second researcher reviewed the coding and initial themes, refining and condensing the themes into 
the dominant themes with the greatest significance to the capacity and infrastructure of the state. 
Finally, the interviewer and first researcher reviewed the refined themes and created a final version for 
which there was consensus among all three (i.e. interviewer, first researcher, and second researcher). 
  
Results of the SWOT analysis are presented below and organized by SWOT category. Participant quotes 
are provided and identified by participant category (i.e. state employee, law enforcement officer, 
healthcare provider, etc.) and random identifier. 
Strengths 
Three overarching strengths emerged regarding prevention of and intervention for prescription opioid 
misuse in Alaska: 
(1) New and revised policies and guidelines 
(2) Activities of and partnerships between state agencies and communities 
(3) Knowledge and awareness of state leadership 
1.) New and Revised Policies and Guidelines 
Participants discussed recent changes to state policies that they believed were advantageous for 
addressing opioid misuse in Alaska. Informants mentioned multiple policies and improvements, 
including new Prescription Drug Monitoring Program (PDMP) regulations, expansion of Alaska Medicaid, 
new legislation providing protection and immunity from arrest and incarceration for certain drug-related 
offenses, and improved access to Naloxone. Though not specific to Alaska, participants also mentioned 
the Center for Disease Control and Prevention’s (CDC’s) guidelines for prescribing opioids for pain 
management as a strength. A state employee (D) suggested this resource could be a useful resource for 
creating prescribing policies in Alaska, saying: 
 “I think we should develop new policies or laws related to prescribing practices. I know the CDC has come out 
with a lot of recommendations.” 
Alaska Senate Bill (SB) 74, passed in 2016, includes two major improvements: new PDMP requirements 
and Medicaid expansion. When asked about policy strengths, a state employee (F) described SB 74, 
saying: 
“SB 74, which was our omnibus Medicaid Reform Bill, [and it] included all the recommendations of the controlled 
substances advisory committee to strengthen the Prescription Drug Monitoring Program.” 
SB 74 imposed new regulations for the use of the PDMP, making it mandatory for prescribers and 
dispensers to register and report weekly on controlled substances prescribed and dispensed. These 
regulations are intended to enhance the ability of providers and dispensers to responsibly and ethically 
provide their patients prescription opioids and reduce non-medical use by patients and others. A state 
employee (K) described the improvements of the bill, stating:  
“…the bill coming up - what's called SB74, the Medicaid Reform Bill - it made some changes as far as access to 
the PDMP. And also, made some mandatory use and registration with it.” 
Though participants acknowledged that these new PDMP requirements do not fully go into effect until 
July 2017, participants nonetheless described the regulations as a significant improvement to the 
Results 
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PDMP’s tracking capability by increasing its use. A state employee (B) described how the changes will be 
meaningful, saying SB 74: 
“…finally made the PDMP useful. That's a Prescription Drug Monitoring Program, and I think that it really wasn't 
very useful, because most doctors didn't use it, and they didn't check it regularly. I think a year from now, it will 
have to – all doctors will have to start, and pharmacists will have to start checking it, and I think that will make a 
difference.” 
Participants also discussed that the new PDMP regulations will improve the ability of PDMP users to 
guard against doctor-shopping behavior (i.e., visiting more than one physician in order to obtain 
multiple prescriptions) among patients. An state employee (K) discussed how these PDMP 
improvements would assist providers, saying: 
“… for some it’s going to be an eye-opener. ‘Wow, I was scammed for a long time… This is someone I've known 
for years and didn't realize I was getting scammed.’” 
Another state employee (F) emphasized the benefit of the PDMP with an example, saying: 
“… (a provider) thought it was a little funny when he had a patient who was five years old with a chronic 
condition that he really was not excited about treating with opioids but was another physician's patient. But he 
(the provider) got a little suspicious when the mother said he (the patient) can't swallow syrup. He likes the 20-
mg pill. And lo and behold when he went on the PDMP he was the third pediatrician she had seen in the past two 
weeks.” 
Overall, participants discussed multiple ways that the PDMP can be an effective method to help 
providers and dispensers recognize when patients are engaging in concerning or illegal behaviors and 
use that information to respond appropriately, including by limiting access to opioids. 
SB 74 also expanded Medicaid to cover treatment for opioid addiction. Participants emphasized that this 
change should make treatment resources more accessible to Alaskans. A state employee (F) described 
this change, saying:  
“So, the Medicaid reform, as well as Medicaid expansion, will help expand access to treatment for people who 
are ‘recovery ready,’ as we say.” 
Participants indicated that treatment access hinges on affordability and having Medicaid pay for this 
type of care would increase people’s access. A healthcare provider (C) explained this further by saying:  
“…we’ll be able to accept Medicaid. Once that happens, that will certainly increase the number of people that 
we’ll be able to address that have opioid use disorders, besides individuals that will self-pay or have insurance.” 
Another Alaska Senate Bill, SB 23, was also identified as a significant policy strength by interview 
participants who indicated the bill removed a major barrier to accessing and administering naloxone. 
Naloxone is medication that can prevent overdose death by reversing the effects of an opioid overdose 
and restoring respiration. In reference to SB 23, a state employee (I) described it as a law that removes 
barriers faced by providers, pharmacists, and responders or the public, saying SB 23 is: 
“…a law providing immunity from civil penalties for prescribing and providing and administering Naloxone.” 
Participants also mentioned Alaska’s Good Samaritan law as a policy strength. The law provides some 
immunity from arrest, charges, and prosecution for possession of certain controlled substances or drug 
paraphernalia for individuals who seek medical assistance during an overdose situation. A state 
employee (D) described this law as:  
“…a mitigation law that encourages emergency treatment of people experiencing drug overdoses, by making the 
act of seeking help in an overdose a mitigating factor in a prosecution or at sentencing.” 
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Participants clarified, though, that this mitigation law only applies to individuals seeking help for 
experiencing an overdose or witnessing another person overdose and that the protection does not 
extend beyond drug possession to other crimes. The same state employee (D) said:  
“Good Samaritan laws do not protect people from arrest for other offenses, such as drug trafficking or selling or 
driving while drugged.” 
Despite some limitations, participants were clear that SB 74, SB 23, and the Good Samaritan law were 
policy strengths for Alaska in that they help prevent opioid misuse and fatal overdoses by reducing the 
availability of opioids for misuse, expanding access to treatment, making a lifesaving drug more available 
to Alaskans, and reducing a major barrier to seeking medical assistance during an overdose situation. 
2.) Activities and Partnerships between State Agencies and Communities  
A second set of strengths identified by participants related to preventing opioid misuse is the array of 
activities and partnerships within and between State of Alaska agencies and Alaskan communities.  
Participants identified numerous activities led by State of Alaska agencies to build support and 
momentum for prevention and intervention, particularly the Alaska Opioid Policy Task Force. The Task 
Force was identified as a major strength for initiating state policy reform by demonstrating a partnership 
between state agencies and community-based agencies. A substance abuse researcher (H) described the 
diverse composition of the task force as a strength in communication and coordination, saying:  
“…the task force includes folks from the board on alcoholism and drug abuse, and they're cooperating and 
collaborating with DHSS and the [Alaska Mental Health] Trust, I think, is probably a clear sign of some of that 
communication and coordination.” 
Participants indicated that having many diverse perspectives increases the group’s ability to make 
informed decisions on policies. A healthcare administrator (L) also described the group’s diversity as 
intentional, saying: 
“…they've created a statewide Opioid Task Force, and this task force was developed to simply pull many 
disciplines across the board together to convene at one table and to discuss how we're going to battle this issue.” 
Participants were especially impressed that the task force actively sought out and included the 
perspectives of people with intimate ties to opioid misuse in their discussions. The same healthcare 
administrator (L) described how impressed she was with the inclusion of people in recovery as well as 
the friends and families of people with an opioid addiction, stating: 
“They really acknowledge the importance of lived experience from families that are affected by this disease, and 
then hearing from individuals in long-term recovery.” 
Participants also identified other efforts within State of Alaska agencies as strengths, including the State 
Epidemiology Workgroup, the State Internal Opioid Working Group, funded community coalitions 
working on PFS, and groups working on other federal grant applications and projects. 
Participants stressed the importance of federal grants to support efforts to prevent and address opioid 
misuse. A state employee (F) emphasized the importance of having federal grants to expand services, 
particularly with the current Alaska fiscal environment, stating: 
“As you're probably aware we have a (fiscal) crisis in Alaska right now. So, it's going to be very limited to what 
we'll be able to do with new unrestricted general funds. So, we are going to be very dependent on some new 
federal funds to be able to address this epidemic.” 
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With federal grant funds, the state has implemented initiatives such as the PFS project, which help the 
state build stronger bonds with community organizations to address each community’s unique needs. A 
substance abuse researcher (H) indicated that the state had received a grant allowing them to fund 
community prevention efforts, saying: 
“I do know that one of the local grantees for that SPF grant that was awarded in Anchorage was awarded to a 
couple of coalitions, and they're collaborating together. So, I know about that collaboration. And my 
understanding is that there was also an award made for one or more groups in Mat-Su…” 
Informants indicated grant funding was so important that some partnerships dedicated group 
responsibilities to searching for more grants targeting opioid misuse. A state employee (D) discussed the 
Internal Opioid Working Group, a partnership between the State of Alaska Divisions of Public and 
Behavioral Health, which has prioritized searching for grants and other funding opportunities as one of 
its primary responsibilities, saying:  
“It (Internal Opioid Working Group) will focus on coordination of future funding opportunities because I know 
there are a lot of federal funding opportunities coming out for this epidemic.” 
Beyond the efforts within State agencies, respondents noted a prominent improvement in collaborative 
efforts between the agencies and community organizations than previously witnessed. A state employee 
(I) described observing a surge in new partnerships because of the rising prevalence of opioid-related 
issues, saying: 
“…I think we're just starting to see more and more partnerships being built. We've always had these partnerships 
on some level, but they're being strengthened as a result of our unified interest and dedication to trying to 
combat this epidemic.”  
Participants discussed improvements in collaborative prevention efforts that expanded the engagement 
of community organizations in prevention and increased communication. Participants described local 
efforts throughout the state, with a state employee (B) saying: 
“And there are of course now a number of local opioid groups that have formed, both in the valley and in 
Fairbanks in the southeast. So, I think there's evidence of a lot of communication and education and advocacy 
going on.” 
A law enforcement officer (G) further described local efforts that exist throughout the state, 
commenting:  
“…there are a lot of smaller homegrown efforts out there as well. I know folks out in the Mat-Su have also been 
very, very engaged and involved, probably on a statewide level, but certainly their focus is in the Mat-Su Valley. 
Same thing down in southeast Alaska. I know in Juneau they've done a lot of work down there…” 
3.) Knowledge and Awareness of State Leadership 
A third strength emerged from participants’ descriptions of state leadership. Participants indicated there 
were some particularly knowledgeable leaders within state agencies and other leaders had, at a 
minimum, a general awareness of the issues. Participants cited the leadership of the State of Alaska 
Divisions of Public and Behavioral Health as particularly knowledgeable and active in prioritizing  
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prevention of and intervention for opioid misuse. Multiple state employees (I; B) acknowledged 
strengths of leadership within these divisions, commenting:  
“…our leadership in the Division of Public Health and the Division of Behavioral Health are very sharp, and really, 
I think, have a lot of expertise and knowledge in this area.”  
“…there are many people, particularly in the Division of Public Health and some in my own division [Behavioral 
Health], who are extremely knowledgeable.” 
At higher levels of state government, the executive and legislative level, participants indicated they were 
aware of the problems, but not necessarily knowledgeable about them. One state employee (F) 
described both branches by saying: 
“The executive branch is very aware. The legislative branch is also very aware.” 
A law enforcement officer (G) echoed the belief that upper-level state leadership was aware but 
described uncertainty about the depth of knowledge, saying: 
“…the state leadership that I'm aware of is paying attention to the legislative discussions, as I said, having met 
with the governor on a couple of occasions, I know they know there are issues out there. But I don't know how 
deep that knowledge is.” 
Weaknesses 
Though participants described considerable improvements to addressing opioid misuse within Alaska 
government agencies and communities, three weaknesses also emerged: 
(1) State policy limitations 
(2) Insufficient detox, treatment, and recovery support resources 
(3) Lack of full coordination within state agencies and with communities 
1.) State Policy Limitations 
Participants agreed there had been considerable improvements made to state policies with more 
improvements planned for the near future, but weaknesses persisted. The areas of weakness focused on 
limitations of the PDMP and the criminal justice approach to addressing substance abuse, including 
opioid misuse.  
For the PDMP, the shortcomings identified surrounded limitations in reporting responsibilities, use, and 
data reporting capabilities. Participants discussed problems caused by limited access to the PDMP. At 
the time of the interviews, only prescribing providers and pharmacists had direct access, meaning they 
were the only people at their organization with access to patients’ records. A state employee (M) 
discussed this limitation of the program’s capabilities and its inconsistent nature compared to most 
other functions within a medical setting, saying:  
“… our program did not allow clinicians to delegate looking up the patient's history on file, even though your staff 
would have complete access to the patient's file.” 
Participants indicated limited access was a problem because time was a major limiting factor for 
providers and dispensers, and just adds more work to an already cumbersome workload. A pharmacist 
(E) often mentioned pharmacists did not have time to check the PDMP, saying: 
“I mean pharmacists do not have time to make phone calls like that [phone calls to providers and other 
pharmacies to inquire about patients’ prescription history], and rarely have time to look somebody up on a 
Prescription Drug Monitoring Program. So, I think it would be very difficult.”   
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The second PDMP weakness identified was a lack of current or forthcoming requirements for providers 
or dispensers to review the database before prescribing or dispensing a controlled substance. A state 
employee (D) described that SB 74 will make only registration and reporting mandatory for providers 
and dispensers, saying: 
“…providers will not be required to check the database before prescribing or dispensing controlled-substances, 
which is a problem.” 
Other participants understood the forthcoming regulations differently. Another state employee (K) 
suggested that providers and dispensers would be required to check the PDMP, saying: 
“…a prescriber, dispenser, if they're going to dispense or prescribe some Schedule II or III, it's mandatory they 
look in the prescription database to see if their patient or client, or whatever, is possibly misused or has another 
prescription for the same material.” 
A second policy weakness identified by participants is the current criminal justice approach to 
preventing and treatment substance abuse. A state employee (F) described this weakness as:  
“Probably the big thing is the criminal justice based approach. That as long as we see opioids as just bad 
decisions and not recognizing that the pathological use is often times addiction and address it as such we're not 
going to be able to solve this.” 
A law enforcement officer (G) further emphasized this same point, saying:  
“…drug or alcohol or substance abuse in general often leads to criminality not because an addict themselves is a 
criminal, but they may enact or engage in criminal behavior to sustain their addiction. And having those open 
and honest discussions, and I think trying to encourage people that are in career path in the law enforcement 
side of the house to have empathy and try to understand that addiction is more than just criminal behavior. 
Sometimes it involves criminal behavior, but oftentimes it does not, and it can affect anybody.” 
A related specific weakness encountered by the criminal justice community is a lack of an established 
diversion program that would allow individuals to be diverted to treatment rather than detention. A law 
enforcement officer (G) explained: 
“Then on the federal side, of course, one of the things that we've been lacking here in Alaska in particular is a 
diversion program…” 
2.) Insufficient Detox, Treatment, and Recovery Support Resources 
A concern identified by nearly all participants was the insufficient availability of detox, addiction 
treatment, and recovery support resources. A human service organization administrator (A) indicated 
the necessity of more detox beds, saying: 
“We don't have enough detox beds, but when you are using that heavy-duty drug as an opioid, you have to go 
somewhere to detox.” 
While some resources exist, participants indicated that they are not readily available to those who need 
more immediate care. Participants described this lack of availability and suggested that it might 
influence whether people seek help. A law enforcement officer (G) described: 
“There just isn't a lot of availability, and for the availability that is there the waiting list is fairly long, and many 
folks know about these types of challenges.” 
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A healthcare administrator (L) further discussed the scarcity of services as a danger to individuals who 
are ready to seek treatment, saying:  
“When somebody decides that they want help or they need help that door needs to be available and open to 
them right away, otherwise it won't take long for them to change their mind or put it off to another day and they 
never ultimately get the help they need.” 
Affordability was another obstacle identified because treatment is expensive, regardless of whether the 
individual has insurance. A healthcare provider (C) described how the current health insurance climate 
does not make treatment affordable for everyone ready to start, stating:  
“There is still a bottleneck, I think, in being able to get in and be seen, whether or not you have insurance or not, 
because not everybody does take Medicaid and then, if you have insurance, there’s a huge deductible and 
treatment isn’t cheap nor are the meds.” 
In addition, participants indicated addiction treatment was only one part of the recovery process as 
struggles with addiction are often lifelong. A healthcare administrator (L) emphasized the necessity of 
continual support, stating: 
“When an individual is sober, their lifelong chronic brain disease, the relapse, will continue for the rest of their 
lives. They constantly need to live a well-balanced life and access ongoing supports and resources.” 
Because of a lack of treatment resources and an established diversion program, people engaging in 
criminal behaviors are frequently incarcerated rather than placed in substance abuse treatment. 
Participants discussed the lack of support for individuals after they are released from incarceration 
which increases their likelihood of relapse and overdose. A healthcare provider (C) with experience 
working in an Alaskan prison stated: 
“…they, of course, would be at increased risk of overdose once they get out. Losing tolerance and then resuming 
drug use.” 
Another barrier mentioned was the particular lack of treatment resources for individuals living in rural 
areas. A healthcare administrator (L) described that some effective treatments are only available in 
cities, saying: 
“…people who are successfully on medications as treatment here in Anchorage, and one that really works for 
them, not one that they have to default to, they may not be able to go home back to their village, because that 
medication is not on the formulary, or that there's no prescriber authorized to provide that type of medication to 
clients out in that village or that region.” 
3.) Lack of Full Coordination within State Agencies and with Communities 
A lack of coordination and communciation among state government agencies, local governments, and 
community groups emerged as another substantial weakness. While respondents indicated observing 
some improvement in coordination, some challenges remained. A substance abuse researcher (H) 
described: 
“I feel like we're probably moving in that direction of communication and coordination, but I think right now 
we're probably more like a seventh-grade dance with people sort of doing some hand-holding, but a little bit of 
tripping over each other's feet as well.” 
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Participants indicated there were still people, state departments, and organizations that were not 
involved that should be. A human services organization administrator (A) said:  
“…there are a lot of departments in our State that people forget ought to be involved in this I think… I don't see 
the Department of Transportation and people are driving when they are high and killing people and I don't see 
the Department of Education and kids are going to school and selling those drugs to their good little friends who 
are in sixth grade or whatever.” 
Participants described that the State of Alaska agencies had not been active enough in engaging other 
departments and community agencies. A law enforcement officer (G) noted that the state coordination 
was inadequate and outreach had often originated from local communities to the state, saying:  
“It doesn't feel to me like somebody's actually behind the scenes coordinating this either at the state level, the 
local level obviously coordinates it, but a lot of times the state partners seem to get invited into these discussions, 
which are very valuable. But if I'm evaluating proactive coordination it seems to me like it's relatively low…” 
Participants also discussed that Alaska’s variety of cultural perspectives had not been represented or 
taken into consideration for existing efforts and activities targeting prescription opioid misuse. A 
healthcare administrator (L) indicated that state-level discussions and coordination did not involve tribal 
health organizations, saying: 
“I know that for my own organization… people felt like there wasn't enough tribal representation.” 
Opportunities 
Three distinct types of opportunities emerged from participants’ responses: 
(1) Education enrichment 
(2) Policy improvements 
(3) Expansion of treatment, recovery, and mental health support 
1.) Education Enrichment 
All participants agreed that an ongoing focus should be on providing education. They suggested belief in 
education as the primary source of change, and the Alaskan population, as a whole, could be more 
educated on this subject. A law enforcement officer (G), asked to describe the three most important 
steps for addressing opioid misuse, said:  
“Education, education and education.”  
Elaborating, the law enforcement officer (G) implied that people needed more education at all levels 
and abstinence-based education would not suffice, saying: 
“I think education, for young people in particular, but for parents, for kids, in the homes, in their schools, in 
community venues, community arenas, and again, not the "Just say no."” 
Participants discussed a number of misconceptions that could be addressed through education. A state 
employee (K) elaborated on people’s misconceptions and knowledge of harm, saying: 
“I think it's going to come back the education part. I think there's a lack of information when it comes to people 
thinking a prescription drug can't hurt you. It's an age old thing but a lot of people think it's a prescription drug 
and it can't hurt you. It's got to be a public education when it comes to also sharing your medication. Just 
because you have an Oxycodone that alleviates your pain, that doesn't mean that the next person should be 
getting that. A lot of people share and sometimes maliciously or sometimes just for a high, but for others it's, 
‘Hey I've got a pain. Well here, take this. This works great for me.’ And there's an education component that's 
just lacking in society.” 
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Participants specifically discussed the need for education regarding the addictive nature of prescription 
opioids. A pharmacist (E) described that clients often did not know the risks associated with their 
prescription and was a subject they should be more aware of, saying: 
“They walk out not knowing how dangerous that prescription can be and how addicting it can be. So, I guess 
awareness of prescription drugs and knowing how similar Vicodin is to heroin.” 
Relatedly, a healthcare provider (J) mentioned how people seemed aware that they should not share 
medications but not necessarily why, stating: 
“I think they know they’re not supposed to share their prescribed medications with other people, but I’m not sure 
that they’re aware of the adverse outcomes that can have.” 
Some recommendations focused on changing how to convey information about substances and opioids 
to young people. A healthcare provider (C) thought that school-based education could be more effective 
if the individuals developing and teaching the curriculums had real-life field experience working with 
individuals who have addictions or have had an addiction themselves, stating:   
“…it would have to be people that are really dealing with the clientele. It can’t be people that are not involved, 
that read a book or read a paper and then try to distill the information. I think it really has to be people that are 
on the ground, on the field, that could be effective.” 
Participants also noted the need to educate parents and adults, both for their own benefit and for the 
opportunity to benefit youth through their influence. For example, increasing adults’ knowledge of how 
to store prescription opioids could limit the availability of this substance to youth and others, decreasing 
the probability of misuse. A state employee (M) emphasized the need for knowledge of proper 
prescription drug storage, stating: 
“Also, increasing and enhancing knowledge and awareness by parents and older adults regarding storage and 
potential misuse of these drugs not only by younger generations, but also by themselves.” 
Education was identified by participants as an opportunity to promote change among all community 
members, including healthcare providers. Participants described that providers should be educated on 
how to prescribe opioids safely, how to help patients when they are dependent, and the importance of 
and how to use the PDMP. Participants discussed that some providers seem to approach prescribing 
situations without considering the potential for, and complications of, addiction. A healthcare provider 
(J) described:  
“I think prescribing any other scheduled substance and not thinking of addiction would be a gap. I think people 
need to think of addiction as they’re prescribing any scheduled substance.”  
Participants indicated concern that some providers and dispensers did not ensure that their patients 
understood the risks associated with prescription opioids. A pharmacist (E) discussed how it is part of 
the job of a provider or dispenser to educate clients, saying: 
“I think that, I guess that we can control on our level is counseling and making sure those patients know what 
they're getting… So, we have to make sure that those people know what they're getting into.”  
Participants also discussed the uncertainty faced by providers when it comes to knowing what to do 
when they suspect or have evidence a patient is misusing opioids. A healthcare provider (C) discussed  
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the opportunity to educate providers about what to do and provide resources that could help providers 
make referrals, saying:  
“And also, outreach to practitioners in: what do you do when you have someone that you are getting 
uncomfortable prescribing opioids to or who you know is coming to you and wants them and you suspect a 
problem? Or, what do you do when you’ve identified a problem? What do you do then? I think that having clear-
cut, easy, pick-up-the-phone, here’s someone, you’re gonna be able to be evaluated quickly in an expeditious 
manner. I think that’s helpful to physicians.” 
Several participants discussed the need for provider education surrounding the PDMP, including 
promotion of the new PDMP policies. A state employee (K) described some ideas to increase awareness 
among providers, saying: 
“I think from the PDMP there needs to be a little more of an awareness of it… It probably needs to do some more 
outreach. Hitting up some of these either associations or hospital type program groups to say, ‘Here's the 
program. Let's use it.’ And how do you give them some examples of its use. It's more of an education.” 
The last group of individuals that participants indicated could benefit from increased education was 
state leaders. Informants had described the existence of some extremely knowledgeable state leaders 
as a strength and also discussed that others would benefit from more complete and data-informed 
information. For example, a state employee (M) identified the legislature as being undereducated, 
saying: 
“The legislature - they have anecdotal knowledge.”  
A law enforcement officer (G) also indicated that state leadership might only have a few referential 
examples but lack a full conceptual understanding, indicating a need for further education, stating:   
 “… our leadership across the state kind of knows and sees what's in the media but maybe don't spend a lot of 
time with the practitioners at any level to really understand what all of that means.” 
2.) Policy Improvements 
Participants identified numerous opportunities to prevent or address opioid misuse through policy 
improvements. First, participants suggested additional revisions to PDMP policies that would decrease 
the burden on providers and increase the accuracy of the data collected. Other policy opportunities 
surround establishing state-specific opioid prescribing guidelines and Medicaid regulations for opioids. 
Finally, participants suggested establishing policies for more protection and immunity from arrest, 
prosecution, and incarceration and to encourage diversion from incarceration into treatment.  
For the PDMP, participants recommended three opportunities for improvement: unsolicited reporting, 
delegate accounts, and increased frequency of reporting. Unsolicited reporting would allow providers to 
receive automatic notifications when a patient has exceeded a prescribing limit, informing them that a 
patient may be doctor shopping. A state employee (D) explained how unsolicited reporting could be a 
useful tool, saying: 
“I think it will allow for providers to receive unsolicited reports, so they don’t actually have to login. They can just 
get an e-mail saying “John Doe exceeded his doctor-shopping threshold. Be on the lookout. Don’t prescribe him a 
controlled substance if he comes in.”” 
Another state employee (K) mentioned how a threshold would trigger an unsolicited report, explaining: 
“They have what they're going to call unsolicited reporting. And basically there's a threshold that the Board of 
Pharmacy has set that says that if you see five prescribers and five pharmacists within a three-month time period 
there's potential that you're doctor shopping…” 
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To address the significant barrier of only allowing prescribing health professionals and dispensers to 
access the PDMP, participants suggested delegate accounts as an opportunity for improvement. A state 
employee (K) described these accounts as: 
“… a delegate account, which would allow any doctor's office who typically says it's onerous for them to have to 
look up a patient, it will allow them to delegate through a licensed associate and, it’s usually a nurse, of some 
kind, to look up the database on their behalf. The same would go with the pharmacy that would allow a 
pharmacy tech type to do it.” 
Both unsolicited reporting and delegate accounts are capabilities that were forthcoming at the time of 
interviews. A state employee (K) described the timeline as:  
“…a lot of these are not taking into effect until July of 2017 which is why they are all kind of off in the future…” 
Participants were inconsistent in their discussions about the PDMP reporting requirements and whether 
they were weekly or monthly. Regardless, participants indicated reporting should be more frequent. A 
number of participants discussed that real-time reporting and access to information is best practice for 
PDMPs. A state employee (D) commented on changes to the reporting requirements, saying in part: 
“Providers will now submit information to the PDMP on a weekly basis. It used to be a monthly basis, so we are 
getting closer to real-time reporting, which is great.” 
Another state employee (B) echoed the suggestion for stricter requirements, stating:  
“In my opinion, we should have said that every prescription had to be entered before you could fill it. That would 
be on a daily basis. And I think we give them a week, which I think is certainly a vast improvement…” 
A substance abuse researcher (H) discussed Alaska’s standards relative to other states, stating: 
“It also sounds like our standards are pretty low relative to other states in terms of the timeliness of reporting, 
and so that also, I think, affects the ability for that data to be utilized, because if you're checking if someone's 
doctor shopping, you might need current up-to-date data in the last 24 hours.” 
A state employee (K) suggested that some pharmacy requirements already dictate reporting daily 
because of company protocols, indicating that such policy is feasible, saying:   
“Many of the pharmacies are already doing it daily and weekly. Just based on it's easier for them because a lot of 
States’ programs, a lot of them are already involved with, especially the chain stores, whether it be Fred Myers, 
Safeway, CVS type. It's easy for them just to comply with whatever their minimum is.” 
Regarding prescribing guidelines, participants indicated that having strict procedural requirements for 
providers and dispensers to follow would benefit the climate. A state employee (D) described the 
absence of straightforward guidelines for prescribers and suggested the belief that these guidelines 
would be an improvement, saying: 
“I think, also, we need to adopt state-wide opioid prescribing guidelines. I don’t think really prescribers across 
Alaska have a consistent, clear set of guidelines to follow in various contexts and with various patient-groups on 
how to appropriately prescribe opioids and how to monitor patients that are taking opioids.” 
Several participants highlighted that monitoring patients, particularly those prescribed opioids for 
chronic pain or medication-assisted treatment (MAT), is essential and suggested policies supporting that 
routine monitoring. Participants further recommended strict regulations for MAT, including monitoring  
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and education training requirements in addiction treatment, particularly with more provider groups 
administering MAT. A healthcare provider (C) explained:  
“I think required CME [Continuing Medical Education] is important. I think that any – with the opening up of 
physician assistants and nurse practitioners to the use of Suboxone, I think it’s important and essential that they 
be linked to a substance use program and that the client attend, and that that be monitored very carefully. I think 
that if this is opened up to mid-levels, they should be – there should be inspection of some sort to make sure that 
this is happening.” 
An additional recommendation, from this participant (C), related to policies for Alaska Medicaid that 
could also be applied to other insurance programs. She said: 
“I think basically anybody on chronic opiates, if they’re on Medicaid, should have one sole-provider. I think that 
would be one law that I would institute. If a person is on Medicaid and is thought to need chronic narcotic 
prescribing for non-cancer pain, then they should have a sole-provider assigned by Medicaid…What it means is 
that this is the person’s primary care physician and any referral outside of that must be made by that 
person…And all prescriptions are usually coming through that person, and I think one pharmacy. I think Medicaid 
– the other thing that should be assigned is one pharmacy. One pharmacy, one provider, if you’re on opiates. 
Period.” 
The final policy opportunity identified by participants relates to the identified weakness of the current 
criminal justice approach to treatment and intervention. Participants recommended providing more 
protection and immunity from arrest, prosecution, and imprisonment for individuals addicted to opioids 
and other substances in order to encourage individuals to seek help. A state employee (D) described 
how current Good Samaritan Laws should be expanded to provide protection beyond possession 
charges, saying: 
“I think we should probably also expand our immunity laws to further protect people from criminal prosecution 
for more than just possession, otherwise I just don’t think we’re going to see the full effect of such immunity.” 
Participants indicated that changing the culture and providing protection and immunity for some 
offenses might allow more people to seek help without worrying that they may face criminal charges or 
imprisonment for the behaviors adopted to sustain their addiction. A state employee (B) explained that 
these behaviors should be treated as a part of addiction as a disease, saying: 
“I still think we could do more with making sure that the police understand sort of what motivates the criminal 
behaviors, so that they treat this more like a disease from which people are sort of looking for answers and are 
very desperate, so that we're not necessarily criminalizing for lengthy periods of time these individuals who do 
trespassing and shoplifting and things like that, that we're not overly criminalizing the behavior if it's resulting 
from just trying to get money to get another hit.” 
Similarly, participants discussed the benefits of a diversion program which involved redirecting an 
individual into treatment instead of jail or prison. A law enforcement officer (G) discussed how diversion 
had worked in other states and described the opportunity for Alaska to implement a diversion program, 
stating: 
“But there is no component, there is no ability to divert out of and away from the penal institution to treatment 
programs. That's usually handled by the courts, and a criminal case has got to be filed. But in many states where 
they've looked at this a little bit differently and because they have the capacity for treatment, law enforcement's 
been given the ability to make that decision to divert an offender right into treatment as opposed to filing a 
criminal charge, or in lieu of, and I think those are things that would be good for us.” 
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3.) Expansion of Treatment, Recovery, and Mental Health Support 
Participants emphasized the expansion of treatment and recovery services as a critical opportunity 
toward prevention and intervention for opioid misuse. As indicated previously in the description of 
weaknesses, participants suggested Alaska did not have enough opioid addiction services available for 
adequate detox, treatment, and recovery options. Recommendations were for comprehensive, holistic 
treatment that covers the continuum from detox through relapse prevention. A healthcare 
administrator (A) discussed comprehensives services as best practices for treatment, saying: 
“I think if I were to summarize what’s working really well, it's a comprehensive approach to dealing with each 
individual. When an individual is, ready and seeking treatment, I think I've learned and recognized and want to 
put forth that it is not about just detoxing. It is not about just accepting that these individuals want treatment. 
It's not about just providing medication-assisted treatment. It's about meeting every individual.” 
Participants indicated that capacity for treatment and recovery services is a major area of opportunity 
because the number of people who need treatment far surpasses the resources and services currently 
available. A state employee (I) discussed MAT as an example, stating: 
“… we need to increase access to medication-assisted treatment, because there are a lot of people out there that 
are ready for treatment, but they are sitting on a waiting list and that’s not okay.” 
A healthcare administrator (L) also mentioned why having better capacity and ample resources available 
were crucial factors, saying: 
“If the individual is ready for treatment, then it's critical and it is happening – some people are successful where 
it's taking a whole – we always say, it takes a whole village to raise a child. Well it takes a lot of resources to help 
somebody get into treatment, and then to stabilize and then come out of treatment and continue to help them to 
stabilize…” 
Respondents also suggested that expansion of services should include harm-reduction methods such 
Naloxone to provide for those who are not ready for or cannot receive treatment. A state employee (I) 
commented on the importance of having Naloxone widely distributed, saying:  
“These are small villages that are now having issues with heroin and probably prescription opioids and we need 
to make sure that there's Naloxone that's available at the village in the small community level and large 
community level.” 
Participants discussed expanded access to and provision of mental health counseling as an opportunity. 
A healthcare administrator (L) described: 
“You can't just prescribe medication as a treatment, because as you know, most if not all of these individuals 
have co-occurring disorders. They have mental health issues in addition to the chronic brain disease of what we 
know as addiction.” 
Other participants focused on mental health promotion and supportive environments as an opportunity 
for prevention. A human service organization administrator (A) stressed the opportunity of ensuring 
good mental health among youth, saying: 
“I think our prevention efforts need to really, really address some of the mental health concerns that drive kids to 
using. Some of that is bullying and dysfunction at home and all sorts of things. But I think if kids can learn early 
on that this is not – you know, there's other things to do to make yourself feel better instead of drugs and 
alcohol…” 
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Additionally, participants identified opportunities to address the barriers of stigma and uncertainty 
related to seeking help for mental health concerns. The same administrator (A) described: 
“… we have to start looking at mental health like it's a sprained ankle, almost. You know? Instead of, "Oh, I can't 
– I don't want to see a mental health professional. That's too scary, but I'll go to the doctor because of this or 
that."” 
Threats 
Four threats to preventing and addressing opioid misuse emerged: 
(1) State fiscal crisis 
(2) Prescribing practices 
(3) Complexity and stigma of addiction 
(4) Legislative support 
1.) State Fiscal Crisis 
Alaska is currently experiencing an economic crisis, and participants indicated that the challenging fiscal 
climate has significantly impacted efforts for opioid misuse prevention and intervention. All participants 
indicated that the lack of resources, including funding and staffing, were limitations that negatively 
impacted day-to-day work and efforts overall. A state employee (I) summed it up succinctly, saying:  
“We need funding.” 
A substance abuse researcher (H) echoed that sentiment:  
“We need sufficient funding…” 
Another state employee (B) mentioned resources were insufficient, saying: 
“I understand that resources widely in the field, particularly right now, are totally tapped out.” 
Participants suggested that these financial issues meant the state prevention capabilities were 
restricted. A state employee (F) discussed the impact on initiatives, saying:   
“… our budget is to the point where we can’t do more with less and we can’t do the same with less. We’ve got to 
do less with less.” 
As discussed in strengths, the Divisions of Public and Behavioral Health have continued to apply for 
more federal grants to compensate for this budget deficit, which they are hoping will bolster their ability 
to provide a variety of prescription opioid misuse services. A state employee (B) described:  
“So, we are going to be very dependent on some new federal funds to be able to address this epidemic.” 
Participants also discussed the limitations of federal funding, describing the funding as restricted in 
scope and timeline. Some participants indicated concerns related to sustainability and indicated that 
funding for opioid misuse prevention and intervention should be covered in the state’s budget. A state 
employee (D) described: 
“We cannot rely on federal grants alone. I think Alaskans need to take accountability for their own problems.” 
Participants described experiencing funding reductions most clearly as reduced and inadequate staff 
across a variety of departments and organizations, from public health nursing to criminal data analytics  
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to community service organizations. A state employee (I) summarized concerns related to staffing, 
stating: 
“…the staff we have are good but the nubmer of staff that we have are insufficient to really stand up to and meet 
the challenge.” 
A state employee (I) elaborated on this point discussing the need for more resources devoted to 
addressing this issue adequately, stating: 
“The big thing is just devoting resources to addressing these issues. We really need the money to be able to fund 
these programs. So that's probably the big catchall in terms of how they can be improved because with the 
resources you've got program people at the health department level. You've got money for expanding treatment 
access, educational outreach, and all sorts of things. That would be the big thing that we could do to improve the 
situation.”  
Participants reflected that good progress is being made on the issue of opioid misuse but that more 
work is needed and that work requires funding. A law enforcement officer (G) stated: 
“I think the state is about middle of the road, and I feel like we're trending upward to become better at it, but 
there is a lot of work to do and this is a very time-consuming and, frankly, expensive proposition, in my humble 
opinion.” 
2.) Prescribing Practices 
Participants identified common prescribing practices of providers as a significant threat. The majority of 
participants described prescribing practices as contributing to prescription opioid misuse, frequently 
mentioning overprescribing as common practice. A healthcare administrator (L) related a personal story 
involving an excessive quantity of opioids, saying: 
“… here's an example, my grandson went to get his wisdom teeth out, right? And he got a prescription for 30 
pills. He's 16 years old.” 
Participants described the culture around pain management and that opioids have become a central 
part of pain management. A pharmacist (E) described:  
“…we believe every time you're in pain you need to treat it with an opioid. Every time you have a toothache or 
anything else, you have to have an opioid for pain. Pain is a natural process. I mean, I don't think that giving an 
opioid is the answer to all pain, and that's just over prescribed. “  
A state employee (K) insinuated overprescribing was indirectly a part of medical training because 
prioritizing pain reduction was a part of providers’ training, stating: 
“I think there's a kind of a lack of understanding. Most of them [healthcare providers] are taught, I think, in my 
own opinion, I think they're taught to alleviate any type of pain. So sometimes that has a tendency of giving 
people more than they think they need or more than they need.” 
Participants emphasized changing prescribing habits will be difficult and creating effective change will 
require changes to medical education. A pharmacist (E) indicated this starts with providers’ initial 
medical education on prescribing and pain management, stating:  
“…it starts with prescribing habits, and that's got to be dealt with and reduced, and for that to happen that has 
to start at the core at, you know, in medical school for that to change prescribing habits, because that's pretty 
hard to change. I mean doctors don't change their prescribing habits easily.” 
While most participants communicated a belief that the problem was overprescribing, a few participants 
also provided perspectives on under-prescribing or decreasing prescription opioid availability. One 
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healthcare provider (J) noted the more severe outcomes that may follow under-prescribing or sudden 
discontinuation, saying: 
“I kind of see it as an overreaction by the medical community so that they aren’t – first they were 
overprescribing, because pain was the fourth vital sign or whatever. Now, they’re really under-prescribing… it’s a 
real mistake to overreact to the people that are having addiction issues to opioids, because then people who may 
need opioids aren’t being prescribed them and then they will go get them somewhere else and then they’re on 
heroin.” 
Others implied similar worry of the consequences for decreasing prescription opioid availability because 
of the persuasive powers of both addiction and pain. A law enforcement officer (G) indicated one 
consequence of reducing prescription opioid availability, saying: 
“I think the downside to that [decrease in OxyContin and oxycodone on the streets] though is it's obviously 
caused a resurgent of heroin and fentanyls and all the other synthetic opioids out there.” 
Overall, participants’ comments reflected the difficulty in ensuring the right balance of prescribing 
opioids for pain management. Despite a lack of clarity on the exact direction of concern, a pharmacist 
(E) emphasized the importance of some kind of change in prescribing behaviors, stating: 
“There is no changing any of it without changing prescribing habits.”  
3.) Complexity and Stigma of Addiction 
Participants identified the complexity of addiction and opioid misuse as a threat to finding solutions. 
They described the need for multiple innovative solutions to address substance use in general and 
opioid misuse specifically. One participant, a healthcare administrator (L), related that some people 
involved are searching for a single, straight-forward solution and disagreed with that approach, saying:  
“Thinking that one piece of the puzzle will solve this is irrational thinking.” 
A healthcare provider (C) described some of the challenges of addiction medicine as:    
 “… this is a complex population. This is not your usual hypertensive, I am diabetic, whatever population. This is 
the population that – with multiple comorbidities, psychiatric comorbidities, and these things have to be caught 
and treated.” 
Participants also identified stigma as a threat to preventing and treating opioid misuse. Many 
participants discussed how stigma interferes with people’s ability to perceive addiction as more than a 
hindrance to society. A state employee (F) described: 
“That as long as we see opioids as just bad decisions and not recognizing that the pathological use is often times 
addiction and address it as such we're not going to be able to solve this.” 
A healthcare adminstrator (L) elaborated on how stigma has been a significant barrier that impacts 
multiple levels, from direct care to policy, saying:   
 “… there's such a stigma. There's a major stigma by those who can prescribe medication-assisted treatment, or 
those who can capture these individuals during a routine medical appointment. There's such a stigma from the 
medical model that these individuals choose to have this chronic brain disease. And once that stigma is lifted, I 
think it'll change even how many of our policy makers make decisions… I think stigma is a huge barrier to some of 
the policies that need to be made, because people think this is a choice. They don't see it as a chronic disease. We 
have a lot of work to do to correct that.” 
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While participants identified stigma as a threat, a few indicated hopefulness that stigma could be 
addressed and stigma reduction would result in positive change. A state employee (M) described stigma 
reduction as a goal, saying:   
“I think that we're going to be removing the stigma of addiction, so that treatment services will be available and 
that for those that are receiving treatment services, there won't be that bounce back from family, friends, other 
of looking down upon them for getting those services.” 
4.) Legislative Support  
Participants indicated that the wavering support of the state legislature on prescription opioid misuse 
prevention initiatives was a barrier to the state government’s ability to increase preventative services. 
Participants identified both lack of funding allocated by the legislature and lack of support for policy 
initiatives as threats.  
One recurring example was recent de-funding of the PDMP. A state employee (D) discussed that the 
legislature should take more responsibility and fund programs like the PDMP, saying:  
“I think we need to have the legislature provide general fund dollars to support the implementation, expansion 
and enhancement of the PDMP instead of relying solely on federal grants and/or registration fees.” 
Some participants indicated lack of legislative support stems from lack of knowledge about the issue or 
misconceptions. One state employee (F) described this threat as:  
“I think there's more misinformation in the legislative branch.” 
Overall, participants indicated that the legislature’s full support is needed in order to provide necessary 
services to address opioid misuse in Alaska. A state employee (D) described the influence of the 
legislature on both funding and policy, saying: 
“We need them [state legislators] to do their job and implement sound policies to protect the health of all 
Alaskans, and we need them to provide dedicated funding to address this crisis.” 
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Overall participants agreed that agencies, communities, and organizations across Alaska have 
demonstrated great concern about the opioid epidemic and that this concern has translated into 
considerable efforts to address and prevent opioid misuse. Participants noted a variety of opportunities 
as targets for future work, many of which would address some of the current weaknesses that exist. 
Additionally, participants articulated a number of real threats to consider going forward.    
While participants’ comments reflected consensus in a variety of the emergent themes, analysis 
revealed discrepancies in two themes. The first was in participants’ perceptions of knowledge among 
state leaders. Some participants believed that state leaders were very knowledgeable about prescription 
opioid misuse as an issue and the climate of prevention in Alaska. Other participants described some 
leaders as only generally aware but not specifically knowledgeable.  
The second discrepancy directly related to the PDMP. Specifically, discrepancies revolved around 
specifics of policy and timing of when the regulations become effective, when certain tools will be made 
available, and reporting frequency requirements. Senate Bill 74, passed in the summer of 2016, 
establishes new policies for the PDMP surrounding mandatory registration and reporting as well as new 
methods for reporting and solicitation of data. Some participants, perhaps because they were less 
knowledgeable about recent changes in legislation, spoke about historical PDMP details that may be 
Discussion 
 
Figure 2: Graphic visualization of SWOT results. Thick colored lines extending to center indicate an 
overlap in the results between SWOT categories; thin lines not extending to center indicate no overlap 
between SWOT categories. 
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changing in the near future. Other participants focused on the upcoming changes to the PDMP. 
Specifically, participants gave mixed responses about when mandatory registration would begin for 
prescribers and dispensers and whether reporting would be required weekly or monthly. Responses also 
varied in relation to when tools such as delegate accounts and unsolicited reporting would be available. 
Lastly, the PDMP checking requirements were debated, with several participants suggesting it was 
compulsory and others indicating reporting to and checking the PDMP were voluntary.  
From the ratified SB74 bill, all changes to the PDMP are effective July 17, 2017 (State of Alaska 29th 
Legislature, 2016). All qualifying prescribers and dispensers must be registered for the AK PDMP and 
weekly reporting on schedule II-IV prescription drugs prescribed and dispensed will be required.3 The 
option to use delegate accounts and receive unsolicited reports will be available on the same effective 
date. Checking the PDMP before prescribing or dispensing is described by legislation as mandatory, but 
how checking will be enforced is unclear. Ultimately, the decision of whether to prescribe or dispense a 
prescription medication is left to the healthcare professional.  
Limitations 
The data collection and analysis process was not without some limitations. Most notably, the sample 
was not entirely representative of state-level stakeholders. Approximately half of those individuals 
invited to participate successfully completed interviews. Therefore, a number of individuals who had 
been identified as holding important positions or likely to have meaningful contributions did not 
participate in an interview. Specifically, no one representing health boards, the military, or legal 
organizations/agencies participated and perspectives from those stakeholder groups may be different 
from those captured through the interviews. Additionally, given the concentration of state employees 
and many healthcare and service agencies in the more populated areas of the state, none of the 
participants specifically represented rural areas.  
The timeline of the interviews also resulted in some limitations. As participants were more difficult to 
recruit than originally anticipated, the recruitment and data collection phases occurred over a period of 
five months. During this time, the Alaska legislature passed multiple relevant bills and state agencies 
received additional grant funding related to prescription opioid misuse. Therefore, depending on when 
they were interviewed, the current status of legislation and efforts varied for participants, which was a 
challenge for analysis.  
Finally, while the PFS project aims to address both prescription opioid misuse and heroin use, the time-
intensive nature of capacity interviews, the limited number of available participants, and the inter-
related nature of the two issues necessitated that the capacity and infrastructure evaluation be limited 
to only prescription opioid misuse. Participants may have different opinions and perspectives on the 
issue of heroin use that were not captured.  
Recommendations 
The primary recommendation from participants focused on education for all Alaskan community 
members, from youth and parents to providers to legislators. Statewide awareness and educational 
campaigns could be used to increase awareness among the public in general and highlight resources for 
more information. Additional educational efforts could target specific needs of various groups. For 
example, youth could be educated about the risks of addiction from prescription medication that may 
                                                   
3 29th Legislature, SB 74, “Medicaid Reform; Telemedicine; Drug Database,” (HCS CSSB 74(FIN) am H), State of 
Alaska: Laws of Alaska 2016, (June 21, 2016). 
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be routinely prescribed and parents may benefit from education and awareness-raising efforts related 
to safe storage of prescription medications.  
Other recommendations suggested by participants included state policies and prescribing guidelines and 
Alaska government agencies are already working on similar efforts. As of January 19, 2017, the AOPTF 
has completed their final recommendations to “increase prevention efforts, enhance addiction 
treatment, and provide better recovery support to reduce misuse in Alaska.” The official 
recommendations can be found on the Alaska Department of Health and Social Services: Alaska Opioid 
Policy Task Force page. This final list of recommendations provides an extensive list of solutions that 
would benefit Alaska.  
On December 30, 2016, the Division of Corporations, Business and Professional Licensing’s Joint 
Committee on Prescriptive Guidelines submitted their recommendation for the adoption of the State of 
Washington’s Interagency Guideline on Prescribing Opioids for Pain, 3rd Ed., with one adaptation – 
reducing the milligram morphine equivalent dose from 120 mg to 90 mg.4 The SB 74 Prescriptive 
Guidelines cover letter can be found on the Board of Pharmacy’s Prescription Drug Monitoring Program 
page. Alaska House Bill 159 was signed into law July 25, 2017 and established requirements for training 
and prescription guidelines.5  
Given the recent changes regarding the PDMP and prescribing guidelines and the corresponding lack of 
clarity among professionals directly impacted by these changes, additional education, training, and 
resources in these areas specific to providers and dispensers is also recommended.  
Conclusion 
The Alaska PFS project aims to reduce and prevent prescription opioid misuse and heroin use. The 
capacity and infrastructure of the State of Alaska is an important factor in the potential success of the 
PFS project. Participants in key informant interviews identified a number of strengths, weaknesses, 
opportunities, and threats in a variety of domains that inform recommendations for enhancing capacity 
and infrastructure. As part of the comprehensive evaluation of the Alaska PFS project, relevant activities 
targeting capacity and infrastructure will be tracked and the extent to which recommendations are 
enacted will be monitored. Additionally, results of these initial interviews will serve as a baseline and be 
compared to results from similar interviews that will be conducted near the end of the project in 2019, 
allowing for determination of potential impact of the PFS project on the state’s capacity and 
infrastructure related to prescription opioid misuse prevention.  
  
                                                   
4 Board of Pharmacy, “SB74 & the Prescription Drug Monitoring Program (PDMP),” Alaska Division of Corporations, 
Business, and Professional Licensing. (January 31, 2017). 
5 30th Legislature, HB 159, “Opioids; Prescriptions; Database; Licenses,” (SCS CSHB 159(FIN)), State of Alaska: Laws 
of Alaska 2017. (June 22, 2017). 
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